Psychological impact of multigene cancer panel testing in patients with a clinical suspicion of hereditary cancer across Spain

2018 ◽  
Vol 27 (6) ◽  
pp. 1530-1537 ◽  
Author(s):  
I. Esteban ◽  
M. Vilaró ◽  
E. Adrover ◽  
A. Angulo ◽  
E. Carrasco ◽  
...  
Keyword(s):  
Hereditary Cancer ◽  
Psychological Impact ◽  
Clinical Suspicion ◽  
Panel Testing ◽  
Cancer Panel

Development of a hereditary cancer panel testing for patients with triple negative breast cancer

The Breast ◽  
2019 ◽  
Vol 44 ◽  
pp. S36-S37
Author(s):  
H. Lee ◽  
K. Lee ◽  
J. Lee ◽  
K. Yoon ◽  
A.M. Mohammad ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Hereditary Cancer ◽  
Triple Negative ◽  
Panel Testing ◽  
Cancer Panel

scholarly journals Apparently Heterozygous TP53 Pathogenic Variants May Be Blood Limited in Patients Undergoing Hereditary Cancer Panel Testing

2020 ◽  
Vol 22 (3) ◽  
pp. 396-404 ◽  
Author(s):  
Jessica L. Mester ◽  
Sarah A. Jackson ◽  
Kristen Postula ◽  
Amy Stettner ◽  
Sheila Solomon ◽  
...  
Keyword(s):  
Hereditary Cancer ◽  
Panel Testing ◽  
Pathogenic Variants ◽  
Cancer Panel

scholarly journals Clinical utility of hereditary cancer panel testing: Impact of PALB2 , ATM , CHEK2 , NBN , BRIP1 , RAD51C , and RAD51D results on patient management and adherence to provider recommendations

Cancer ◽  
2019 ◽  
Vol 126 (3) ◽  
pp. 549-558 ◽  
Author(s):  
Valentina Vysotskaia ◽  
K. Eerik Kaseniit ◽  
Leslie Bucheit ◽  
Kaylene Ready ◽  
Kristin Price ◽  
...  
Keyword(s):  
Hereditary Cancer ◽  
Clinical Utility ◽  
Patient Management ◽  
Panel Testing ◽  
Cancer Panel

Mosaic TP53 pathogenic variants on multi-gene hereditary cancer panel testing: Clinical characteristics and follow-up testing.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. 1580-1580
Author(s):  
Sarah A. Jackson ◽  
Maegan Roberts ◽  
Jessica L. Mester ◽  
Megan L. Marshall ◽  
Kristen J. Vogel Postula ◽  
...  
Keyword(s):  
Hereditary Cancer ◽  
Clinical Characteristics ◽  
Panel Testing ◽  
Pathogenic Variants ◽  
Cancer Panel

scholarly journals Germline multi-gene hereditary cancer panel testing in an unselected endometrial cancer cohort

2016 ◽  
Vol 29 (11) ◽  
pp. 1381-1389 ◽  
Author(s):  
Kari L Ring ◽  
Amanda S Bruegl ◽  
Brian A Allen ◽  
Eric P Elkin ◽  
Nanda Singh ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Hereditary Cancer ◽  
Panel Testing ◽  
Cancer Panel

scholarly journals Hereditary cancer panel testing in an unselected endometrial carcinoma cohort

2016 ◽  
Vol 141 ◽  
pp. 10-11
Author(s):  
K.L. Ring ◽  
A.S. Bruegl ◽  
B.A. Allen ◽  
E.P. Elkin ◽  
N.U. Singh ◽  
...  
Keyword(s):  
Endometrial Carcinoma ◽  
Hereditary Cancer ◽  
Panel Testing ◽  
Cancer Panel

Multigene hereditary cancer panel testing for patients with pancreatic cancer.

2017 ◽  
Vol 35 (4_suppl) ◽  
pp. 244-244
Author(s):  
Anna K McGill ◽  
Sheila R Solomon ◽  
Megan L Marshall ◽  
Lisa Susswein ◽  
Corrine Fillman ◽  
...  
Keyword(s):  
Family History ◽  
Hereditary Cancer ◽  
Diagnostic Yield ◽  
Ductal Adenocarcinoma ◽  
Panel Testing ◽  
Pathogenic Variants ◽  
Gene Panel Testing ◽  
History Of ◽  
Brca1 Brca2 ◽  
Cancer Panel

244 Background: Pancreatic ductal adenocarcinoma (PC) is associated with multiple hereditary cancer syndromes. Genes implicated in hereditary PC include ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2 and PMS2. The advent of multi-gene hereditary cancer panel testing streamlines diagnoses and medical management for clinicians and patients. Our objective was to assess the yield of pathogenic/likely pathogenic variants (PV/LPV) in individuals with PC undergoing panel testing as an initial test at GeneDx. Methods: We retrospectively reviewed panel test results of 605 individuals reporting a personal history of PC. Panel testing evaluated up to 32 genes associated with hereditary cancer. Individuals reporting neuroendocrine pathology or previous BRCA1/BRCA2 testing were excluded. Results: In this cohort, 61 PV/LPV were detected in 57 individuals in the following genes: ATM (17), BRCA2 (14), BRCA1 (5), CDKN2A (5), PALB2 (5), CHEK2 (4), MLH1 (2), MUTYH (2), PMS2 (2), BARD1 (1), FANCC (1), MSH2 (1), RAD51D (1) and TP53 (1), corresponding to a positive yield of 9.4% (57/605). Fifty-one of 61 PV/LPV were detected in genes associated with PC (84%) while 10 PV/LPV (16%) were identified in other genes including BARD1, CHEK2, FANCC, MUTYH, and RAD51D. The diagnostic yield among those reporting a family history of PC (33/294, 11.2%) was not statistically different from those without a reported family history (24/311, 7.7%). However, PV/LPV in ATM were detected more often in individuals reporting a family history of PC compared to those without a family history (4.1% vs. 1.6%, p=0.018). Conclusions: In total, 9.4% of patients with PC tested positive for PV/LPV in 14 different genes by panel testing. Although the majority of PV/LPV were identified in known PC genes, 16% of positive findings occurred in genes not typically associated with PC. ATM was most commonly implicated and more frequently reported in patients reporting family histories of PC. Assessing whether these genes are indeed causally related to PC and/or are possibly associated with other cancer types requires further investigation. Based on our results we conclude multi-gene panel testing may be considered as a first option for patients with PC regardless of their family history.

scholarly journals A Life Potentially Saved Through Hereditary Cancer Panel Testing

2017 ◽  
Vol 13 (4) ◽  
pp. 279-281
Author(s):  
Dustin Marks ◽  
Allison McHenry ◽  
Tara Biagi ◽  
Elizabeth Stark ◽  
Marie Borum ◽  
...  
Keyword(s):  
Hereditary Cancer ◽  
Panel Testing ◽  
Cancer Panel

MG-107 Multiple pathogenic variants identified by next-generation sequencing hereditary cancer panel testing – a case report

2015 ◽  
Vol 52 (Suppl 2) ◽  
pp. A3.1-A3
Author(s):  
Christopher A Tan ◽  
Marina Rabideau ◽  
Stephanie Cohen ◽  
Shan Yang ◽  
Karen Vikstrom ◽  
...  
Keyword(s):  
Case Report ◽  
Next Generation Sequencing ◽  
Hereditary Cancer ◽  
Next Generation ◽  
Panel Testing ◽  
Pathogenic Variants ◽  
Generation Sequencing ◽  
Cancer Panel
Sign in / Sign up

Export Citation Format

Share Document